Fresenius SE & Co. KGaA (ETR:FRE)
Germany · Delayed Price · Currency is EUR | Market Cap | 27.59B |
| Revenue (ttm) | 22.45B |
| Net Income (ttm) | 1.14B |
| Shares Out | 563.24M |
| EPS (ttm) | 2.03 |
| PE Ratio | 25.24 |
| Forward PE | 13.54 |
| Dividend | 1.00 (2.04%) |
| Ex-Dividend Date | n/a |
| Volume | 242,377 |
| Average Volume | 708,216 |
| Open | 48.80 |
| Previous Close | 48.69 |
| Day's Range | 48.50 - 48.98 |
| 52-Week Range | 31.60 - 50.74 |
| Beta | 0.94 |
| RSI | 58.94 |
| Earnings Date | Mar 25, 2026 |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The company was formerly know... [Read more]
Financial Performance
Financial StatementsNews
Fresenius SE & Co. KGaA (FSNUY) Analyst/Investor Day Transcript
Fresenius SE & Co. KGaA (FSNUY) Analyst/Investor Day December 15, 2025 7:00 AM ESTCompany ParticipantsNick Stone - Senior VP of Investor Relations &...
Fresenius SE & Co. KGaA (FSNUY) Analyst/Investor Day - Slideshow
DaVita: More Volatile But Better Upside Than Fresenius
Discover why DaVita (DVA) is rated a speculative Buy despite risks.
Fresenius Launches Denosumab Biosimilars
(RTTNews) - Fresenius (FRE.DE) announced the launch of its denosumab biosimilars, Conexxence and Bomyntra, in Europe. The biosimilars received approval from the European Commission in July 2025 for al...
EQS-PVR: Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe...
EQS-AFR: Fresenius SE & Co. KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: Fresenius SE & Co. KGaA / Preliminary announcement on the disclosure of financial statements Fresenius SE & Co. KGaA: Preliminary announcement of the pu...
EQS-AFR: Fresenius SE & Co. KGaA: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Fresenius SE & Co. KGaA / Preliminary announcement on the disclosure of financial statements Fresenius SE & Co. KGaA: Preliminary announcement of the pu...
Fresenius SE & Co. KGaA 2025 Q3 - Results - Earnings Call Presentation
2025-11-05. The following slide deck was published by Fresenius SE & Co.
Fresenius SE & Co. KGaA (FSNUY) Q3 2025 Earnings Call Transcript
Fresenius SE & Co KGaA (FSNUF) Q3 2025 Earnings Call Highlights: Strong Core EPS Growth and ...
Fresenius SE & Co KGaA (FSNUF) Q3 2025 Earnings Call Highlights: Strong Core EPS Growth and Raised EBIT Guidance Amid Market Challenges
Q3 2025 Fresenius SE & Co KGaA Earnings Call Transcript
Q3 2025 Fresenius SE & Co KGaA Earnings Call Transcript
Fresenius (FSNUF) Q3 Earnings Miss Expectations Amid Revenue Shortfall
Fresenius (FSNUF) Q3 Earnings Miss Expectations Amid Revenue Shortfall
Fresenius SE& Co. misses Q3 estimates
Fresenius SE & Co. KGaA 2025 Q2 - Results - Earnings Call Presentation
Fresenius SE & Co. KGaA (FSNUF) Q2 2025 Earnings Call Transcript
Our U.S. investment has protected us - Fresenius CEO
Fresenius has raised its revenue outlook for the full-year, with the German healthcare group now expecting up to 7% organic growth. CEO Michael Sen tells CNBC's Silvia Amaro the company's local-to-loc...
Fresenius Lifts Full-Year Sales Outlook as Revamp Gains Momentum
Fresenius SE lifted its full-year sales outlook after a strong performance by the German health-care group’s hospitals and Kabi, its biopharma and MedTech unit.
EQS-PVR: Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe...
Fresenius: Healthy Portfolio Add
Fresenius medical care outlines 2025 operating income growth targets amid strategic transformations
Fresenius SE & Co. KGaA 2025 Q1 - Results - Earnings Call Presentation
Fresenius SE & Co. KGaA (FSNUF) Q1 2025 Earnings Call Transcript
Fresenius SE & Co. KGaA reports Q1 results
Fresenius posts profit beat in first quarter, confirms outlook
German healthcare group Fresenius beat analysts' adjusted operating profit expectations for the first quarter on Wednesday, citing a strong performance at its drug making division Kabi.